Aadel Chaudhuri, MD PhD (@aadel_chaudhuri) 's Twitter Profile
Aadel Chaudhuri, MD PhD

@aadel_chaudhuri

ctDNA Liquid Biopsy | Vice Chair of Translational Research @MayoRadOnc | Co-Director of Cancer Precision Medicine & Emerging Leader @MayoCancerCare @MayoClinic

ID: 911249380329402368

linkhttps://www.mayo.edu/research/faculty/chaudhuri-aadel-a-m-d-ph-d/bio-20568129 calendar_today22-09-2017 15:22:37

6,6K Tweet

2,2K Followers

829 Following

Wendy Woodward MDPhD (@ibcradiation) 's Twitter Profile Photo

Keytruda combined with SBRT was associated with higher rates of adverse events (AEs), including AEs leading to death, compared with SBRT and placebo. #radonc finance.yahoo.com/news/merck-pul…

Dr. Patrick Hwu (@patrickhwumd) 's Twitter Profile Photo

#ScienceSaturday The combination of anti-CTLA-4 and anti-PD-1 antibodies is FDA approved for the treatment of advanced #melanoma. How does this combination work mechanistically? In a recently published study in Cancer Cell using both single cell TCR and RNA sequencing, Wang

#ScienceSaturday 

The combination of anti-CTLA-4 and anti-PD-1 antibodies is FDA approved for the treatment of advanced #melanoma. How does this combination work mechanistically?  In a recently published study in <a href="/Cancer_Cell/">Cancer Cell</a> using both single cell TCR and RNA sequencing, Wang
Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer Out on Clinical Cancer Research Study investigates metastatic castration-resistant #ProstateCancer (mCRPC) resistant to androgen receptor signaling

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer Out on <a href="/CCR_AACR/">Clinical Cancer Research</a>

Study investigates metastatic castration-resistant #ProstateCancer (mCRPC) resistant to androgen receptor signaling
Aadel Chaudhuri, MD PhD (@aadel_chaudhuri) 's Twitter Profile Photo

Thank you Clinical & Translational Epidemiology Unit - MGH for the hospitality — Enjoyed meeting the brilliant and vibrant group and sharing our liquid biopsy insights from Mayo Clinic Radiation Oncology Mayo Clinic Comprehensive Cancer Center with you. And really enjoyed a great North End Italian dinner. 😋 Special thx to Dr. Long Nguyen for the invite!

Thank you <a href="/MGH_CTEU/">Clinical & Translational Epidemiology Unit - MGH</a> for the hospitality — Enjoyed meeting the brilliant and vibrant group and sharing our liquid biopsy insights from <a href="/MayoRadOnc/">Mayo Clinic Radiation Oncology</a> <a href="/MayoCancerCare/">Mayo Clinic Comprehensive Cancer Center</a> with you.

And really enjoyed a great North End Italian dinner. 😋

Special thx to Dr. Long Nguyen for the invite!
Taylor Sundby, MD 🧬 (@rtsundby) 's Twitter Profile Photo

1/ Can #liquidbx detect pre-malignancy & guide intervention to avert cancer before it develops? Our recent NCI Center for Cancer Research -Mayo Clinic-WashU Medicine led collaboration’s Clinical Cancer Research publication (shorturl.at/amWS2) suggests that it can in #neurofibromatosis (NF1). A 🧵:

Aadel Chaudhuri, MD PhD (@aadel_chaudhuri) 's Twitter Profile Photo

At one of the most exciting events of the year: Mercy Precision Medicine Summit, in St. Louis! I’ll be delivering the keynote on liquid biopsy — Current use + Future potential + Our precision Onc research Mayo Clinic Radiation Oncology Mayo Clinic Comprehensive Cancer Center. Thank you Gautum Agarwal for the invite!

Neurofibromatosis Therapeutic Acceleration Program (@ntapresearch) 's Twitter Profile Photo

NTAP was proud to support a publication from one of our #FrancisSCollinsScholars, Dr. Taylor Sundby, MD 🧬, in AACR’s Clinical Cancer Research journal. The article details a cfDNA fragmentomic approach to distinguish between forms of PNST in #NF1. Read more: bit.ly/4gc6FSU #neurofibromatosis

Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Sharing an instructive case. Treated isolated liver met single fx SBRT (40Gy). ctDNA 5 days later increased 80 to 1100!! PET 2 wks after negative (tumor gone), & ctDNA 3 wks later <10. Lesson - if checking ctDNA, wait (at least a few wks?) after SBRT. Have others seen this?

Sharing an instructive case. Treated isolated liver met single fx SBRT (40Gy). ctDNA 5 days later increased 80 to 1100!!

PET 2 wks after negative (tumor gone), &amp; ctDNA 3 wks later &lt;10.

Lesson - if checking ctDNA, wait (at least a few wks?) after SBRT.

Have others seen this?
Volastra Therapeutics (@volastratx) 's Twitter Profile Photo

Our co-founder, Dr. Samuel Bakhoum’s pioneering work linking #chromosomal_instability (CIN) to #cancer progression forms the backbone of our research strategy which exploits CIN to develop transformative treatments for cancer patients. FierceBiotech: bit.ly/4g8NzgG

Michal Tal, PhD (@immunofever) 's Twitter Profile Photo

Irv used to teach this class Stanford Stem Cell. No homework. When you arrived he would reveal the title of a paper he thought was foundational. The class would have to come up with which experiments would have been required to back up a title like this. Truly great thought exercise!

Aadel Chaudhuri, MD PhD (@aadel_chaudhuri) 's Twitter Profile Photo

Indeed, we’re working on the next step with Children's Tumor Fdn & Mayo Clinic Pathology toward translating these findings into the clinic! Truly grateful to Children's Tumor Fdn for all their support. Our recent paper & current translation efforts wouldn’t have been possible without it.

Rahul Tendulkar, MD (@rtendulkarmd) 's Twitter Profile Photo

Matthew Walker Cleveland Clinic Lerner College of Medicine Absolutely. First it starts with leaders who prioritize the wellness of their physicians, as it promotes engagement, retention, recruitment, & productivity. Here’s a great example: